© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011

CUSP for VAP: EVAPNHSN VAE Surveillance Definition ReviewPresented by:Kathleen Speck, MPHAugust 23, 2012 Armstrong Institute for Patient Safety and Quality

CUSP for VAP: EVAP Project Overview

• NIH/NHLBI and AHRQ funded project– Individual hospitals participate for 3 years,

including 2 year intervention period and 1 year evaluation of sustainability

• Leveraging leaders in field – Armstrong Institute for Patient Safety and

Quality, NIH/NHLBI, CDC, AHRQ, University of Pennsylvania, MHA and HAP

2

NIH/NHLBI - National Institutes of Health, National Heart, Lung, and Blood Institute; AHRQ -Agency for Healthcare Research and Quality

Our Collaborators

– Karol G. Wicker, MHSSenior Director, Quality Policy & AdvocacyMaryland Hospital Associationkwicker@mhaonline.org

– Mary Catanzaro RN BSMT CIC Project Manager HAIs Hospital and Healthsystem Association of Pennsylvaniamcatanzaro@haponline.org

3

Who can join CUSP for VAP: EVAP?

• Participation in the program is available to any facility with mechanically ventilated patients in Maryland and Pennsylvania.

• Hospital participation will be coordinated with state hospital association or hospital engagement network (HEN).

Armstrong Institute for Patient Safety and Quality4

Learning Objectives

• To become more comfortable with the new VAE surveillance definitions

• To become familiar with a linelist generation tool and workbook developed by Michael Klompas, MD, MPH, FRCPC

Armstrong Institute for Patient Safety and Quality5

History of NHSN VAE Surveillance Definition

• Current NHSN VAP surveillance definition– Subjective

• Not sensitive or specific1-3

• Requires radiographic findings – often unclear• Requires clinical signs and symptoms• Doesn’t allow accurate validation of success of prevention

strategies4-7

• Doesn’t allow establishment of valid benchmarks

6

1. Klompas M, JAMA 20022. Klompas M, Am J Infect Control 20103. Klompas M, et al, Clin Infect Dis 20084. Zilberberg MD, et al, Clin Infect Dis 2010

5. Girard T, et al, Lancet 20086. Strom T, et al, Lancet 20107. The Acute Respiratory Distress Syndrome

Network , N Engl J Med 2000

Development of new VAE Surveillance Definition

• Working group – 2011– Critical Care Societies Collaborative– American Association for Respiratory Care– Association of Professionals in Infection Control

and Epidemiology– Council of State and Territorial Epidemiologists– Healthcare Infection Control Practices Advisory

Committee’s Surveillance Working Group– Infectious Diseases Society of America– Society for Healthcare Epidemiology of America

Armstrong Institute for Patient Safety and Quality7

NHSN VAE Definition

• Objective • Streamlined• Potentially automatable• Will define a broad range of conditions and

complications occurring in mechanically ventilated patients

Armstrong Institute for Patient Safety and Quality8

Which locations should use VAE surveillance?8

• Inpatient – Acute care hospitals– Long term care hospitals– Rehabilitation facilities

• Unit type (examples)– Critical/intensive care units– Specialty care units– Step-down units– Long term care units

Armstrong Institute for Patient Safety and Quality9

Inclusions and Exclusions for VAE Surveillance in 2012 -20138

• Excluded patients:– < 18 years of age– on high frequency ventilation or extracorporeal

life support• Included patients:

– ≥ 18 years of age– Receiving conventional mode of mechanical

ventilation while prone or while receiving nitric oxide or epoprontenal therapy

– On APRV or related therapy• Use changes in PEEP only

Armstrong Institute for Patient Safety and Quality10

OTHER VAE ASSOCIATED DEFINITIONS8

VAE Definition Tiers8

12

NHSN Surveillance 2012-2013

• Assessment must take place for all VAE tiers– VAC - Ventilator-associated Condition– IVAC - Infectious Ventilator-associated

Condition– Possible VAP – Possible Ventilator-

associated Pneumonia– Probable VAP – Probable Ventilator-

associated Pneumonia

Armstrong Institute for Patient Safety and Quality13

VAC Definition Criteria8

• Patient intubated for > 2 calendar days• Baseline stability

– Baseline time period:• The 2 calendar days immediately preceding the

first day of increased daily minimum PEEP or FiO2

– Stability:• The same 2 calendar days with stable or

decreasing daily minimum PEEP or FiO2

Armstrong Institute for Patient Safety and Quality14

Example - VAC

Armstrong Institute for Patient Safety and Quality15

Example – no VAC

Armstrong Institute for Patient Safety and Quality16

Subsequent VAEs

• The time period for a VAE is 14 days– Starts on day 1 of worsening oxygenation– New VAE cannot be reported until 14 day

period has elapsed

Armstrong Institute for Patient Safety and Quality17

Episode of Mechanical Ventilation

• A period of days during which the patient is mechanically ventilated for at least a portion of each day.

Armstrong Institute for Patient Safety and Quality18

New Antimicrobial Agent

• Any agent listed in the Appendix of the Device Associated Events: VAE (pages 10-19 through 10-21) that:– Is initiated on or after the third day of mechanical

ventilation AND – is given in the 5 day period defined by

• 2 days before • the day of• the 2 days after

AND– Was not given to the patient on either of the two days

preceding the current start date

Armstrong Institute for Patient Safety and Quality19

Date of Event

• The date of onset of worsening oxygenation– First calendar day in which minimum PEEP

and FiO2 increases above thresholds in the VAE algorithm

Armstrong Institute for Patient Safety and Quality20

DETERMINATION OF A VAE

VAE Outcomes

• VAE = VAC, IVAC, Possible VAP and Probable VAP

• VAC = Significant respiratory deterioration after 2 or more days of stability

• IVAC = VAC + abnormal temp or WBC + ≥ 4 days of new antibiotics

• Possible VAP = IVAC + purulent sputum or positive sputum/BAL culture

• Probable VAP = IVAC + purulent sputum AND positive sputum/BAL culture

Armstrong Institute for Patient Safety and Quality22

Setting Up a Linelist

Armstrong Institute for Patient Safety and Quality23

Linelist Generator, developed by Michael Klompas, MD, MPH, FRCPC

• Will help you apply the new CDC VAE criteria• Will automatically flag VAC, IVAC, possible

VAP and probable VAP

Armstrong Institute for Patient Safety and Quality24

Linelist Definitions

Armstrong Institute for Patient Safety and Quality25

Steps to generate linelist for VAE

• Begin with “Daily Linelist”• Enter patient identifier, date, daily minimum

PEEP and FiO2 for every ventilated patient for every calendar day the patient spends any time on a ventilator

• Worksheet will automatically flag events that fulfill criteria for VAC

• If a patient is not identified as having VAC, don’t collect any further information for that patient.

Armstrong Institute for Patient Safety and Quality26

Determination of VAC

• After period of stability or improvement on the ventilator the patient has at least one of these indicators of worsening oxygenation– Daily min FiO2 values increase ≥ 0.20 over

daily min for preceding 2 calendar days– Daily min PEEP values increase ≥ 3 cm H2O

over daily min for the preceding 2 calendar days

Armstrong Institute for Patient Safety and Quality27

Step 1 – VAC

Armstrong Institute for Patient Safety and Quality28

Determination of IVAC

• Only look at patients where VAC has been determined

• Enter:– Tmin and Tmax– WBCmin and WBCmax – QAD – Qualifying antibiotic day

• IVAC requires 4 contiguous days of a new antibiotic starting within the 5 days starting 2 days before the onset

Armstrong Institute for Patient Safety and Quality29

Step 2 - IVAC

Armstrong Institute for Patient Safety and Quality30

Determination of Possible VAP or Probable VAP

• Only look at patients where IVAC has been determined

• From Sputum of BAL gram stain– Enter

• Polys – polys, neutrophils or WBC (semiquantitative scale)

• Epis – epithelial cells or squamous cells (semiquantitative scale)

• Culture – result• Quantity - threshold (10^5 for endotracheal aspirate,

10^4 for BAL, 10^3 for protected specimen brush). Semi-quantitative equivalent also acceptable. Answer Yes or No.

Armstrong Institute for Patient Safety and Quality31

Semiquantitative Scale for Polys and Epis

Armstrong Institute for Patient Safety and Quality32

None Enter 0Few, rare, ≤10 cells/lpf Enter 1Moderate, ≥25 cells/lpf Enter 2Many Enter 3Abundant Enter 4

Step 3 – Possible VAP or Probable VAP

Armstrong Institute for Patient Safety and Quality33

NHSN Event Report 1st Page (Top) - Patient Information

Armstrong Institute for Patient Safety and Quality34

NHSN Event Report 1st (Bottom)Page – Event Details

Armstrong Institute for Patient Safety and Quality35

Next Steps

• If your hospital is participating in this project, you will be receiving– Draft CDC Device-associated Events – VAE

manual– Draft revised VAE reporting form– Dr. Klompas’ worksheet for VAE Linelist

generation• Next week – Q & A on CDC reporting manual

and reporting form

Armstrong Institute for Patient Safety and Quality

36

Enrollment

• If your hospital is not participating in the project and you are interested, please contact your hospital association representative

– Karol G. Wicker, MHSSenior Director, Quality Policy & AdvocacyMaryland Hospital Associationkwicker@mhaonline.org

– Mary Catanzaro RN BSMT CIC Project Manager HAIs Hospital and Healthsystem Association of Pennsylvaniamcatanzaro@haponline.org

37

• Questions?

Armstrong Institute for Patient Safety and Quality38

39

References

1. Klompas M. Does this patient have ventilator-associated pneumonia? Jama 2007 Apr 11;297(14):1583-93.

2. Klompas M. Interobserver variability in ventilator-associated pneumonia surveillance. Am J Infect Control. 2010 Apr;38(3):239-9. Epub 2010 Feb 19.

3. Klompas M, Kulldorf M, Platt R. Risk of misleading ventilator-associated pneumonia rates with use of standard clinical and microbiological criteria. Clin Infect Dis. 2008 May 1;46(9):1443-6.

4. Zilberberg MD, Shorr AF. Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S131-5.

5. Girard TC, Kress JP, Fuchs BD, Thomason JW, Schweikert WD, Pun BT, Taichman DB, Dunn JG, Pohlman AS, Kinniry PA, Jackson JC, Canonico AE, Light RW, Shintani AK, Thompson JL, Gordon SM, Hall JB, Dittus RS, Bernard DR, Ely EW. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomized controlled trial. Lancet. 2008 Jan 12;371(9607):126-34.

40

References

6. Strom T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomized controlled trial. Lancet. 2010 Feb 6;375(9713):475-80. Epub 2010 Jan 29.

7. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000 May 4;342(18):1301-8.

8. Draft – CDC Device-associated Events VAE, Ventilator-Associated Event.

9. Klompas M. Linelist Generator Workbook. Not published.